Valuation: Satellos Bioscience Inc.

Market Cap 150M 131M 121M 113M 212M 14.13B 217M 1.45B 563M 6.98B 562M 550M 24.21B P/E 2026 *
-4.19x
P/E 2027 * -4.48x
Enterprise Value 56.1M 49.19M 45.34M 42.45M 79.6M 5.29B 81.26M 545M 211M 2.62B 211M 206M 9.07B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
93.51%
Yield 2026 *
-
Yield 2027 * -
1 day+6.03%
1 week+25.15%
Current month+0.99%
1 month+9.09%
3 months+6.25%
6 months+26.87%
Current year+28.79%
1 week 7.76
Extreme 7.76
10.2
1 month 7.76
Extreme 7.76
10.26
Current year 7.67
Extreme 7.67
18.98
1 year 6.36
Extreme 6.36
18.98
3 years 3.48
Extreme 3.48
18.98
5 years 2.58
Extreme 2.58
22.8
10 years 2.58
Extreme 2.58
22.8
Manager TitleAgeSince
Chief Executive Officer 70 28/02/2018
Chief Tech/Sci/R&D Officer - 30/04/2018
Director of Finance/CFO - 31/08/2023
Director TitleAgeSince
Chairman 59 30/06/2018
Director/Board Member 50 28/02/2018
Director/Board Member 70 30/06/2012
Date Insider Type Main position Quantity % Market Cap.
04-06Buy

Director

5,500 0.0356%
04-06Buy

Director

4,500 0.0291%
04-06Option

Founder

108,630 0.7027%
Change 5-day change 1-year change 3-year change Capi.($)
+6.03%+25.15%+39.34%+70.00% 150M
+0.33%+1.37%+64.03%+119.11% 55.63B
+0.82%+15.05%+79.93%+84.34% 52.25B
+1.36%+0.36%-14.06%-14.69% 23.07B
-1.04%+7.91%+1.61%+419.24% 22.41B
-0.18%+7.20%+32.16%-14.07% 17.32B
-1.10%+4.00%+28.70%-34.51% 15.94B
-3.35%+8.96%+132.20%+290.18% 13.47B
+2.89%+5.51%+27.11%+181.45% 13.77B
+1.31%+0.53%+28.62% - 12.43B
Average +0.71%+6.81%+41.96%+122.34% 22.64B
Weighted average by Cap. +0.27%+5.15%+48.49%+120.14%

Financials

2026 *2027 *
Net sales - -
Net income -46.27M -40.57M -37.4M -35.01M -65.65M -4.36B -67.01M -449M -174M -2.16B -174M -170M -7.48B -57.06M -50.03M -46.11M -43.17M -80.96M -5.38B -82.64M -554M -214M -2.66B -214M -210M -9.22B
Net Debt -93.65M -82.11M -75.69M -70.86M -133M -8.83B -136M -910M -352M -4.37B -352M -344M -15.14B -111M -97.63M -89.99M -84.25M -158M -10.5B -161M -1.08B -419M -5.19B -418M -409M -18B
Logo Satellos Bioscience Inc.
Satellos Bioscience Inc. is a Canada-based clinical-stage drug development company. The Company is focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, the Company has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. It is also leveraging its proprietary discovery platform MyoReGenX to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process.
Employees
20
Date Price Change Volume
26/06/26 CA$10.20 +6.03% 10,782
25/06/26 CA$9.620 +21.31% 27,902
24/06/26 CA$7.930 +0.51% 6,244
23/06/26 CA$7.890 -1.50% 15,198
22/06/26 CA$8.010 -1.72% 530
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
10.20CAD
Average target price
15.33CAD
Spread / Average Target
+50.33%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MSCL Stock